This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Australia
AdAlta has significant expertise and proprietary libraries that will enable the discovery and identification of lead candidates.
The single domain shark antibody technology and the humanised version (i-body) have been developed into libraries containing a billion or more molecules that can be used to identify binders to a particular target to identify novel drug and diagnostic candidates.
Shark antibodies and i-bodies have high specificity and affinity for various therapeutic and diagnostic targets. They also have a number of advantages compared to traditional antibodies including a unique binding structure, specifically a very long CDR3 loop that can bind into hydrophobic grooves and receptor sites, providing the potential to bind drug targets that cannot be addressed by traditional antibodies. Shark antibodies and i-bodies are naturally small providing an ability to target various diseases more effectively and are manufactured in bacterial systems. Both the shark antibody and i-body are extremely stable at high temperatures and low pH for extended periods of time, giving rise to alternative delivery mechanisms beyond injection.
The single domain shark antibody technology and the humanised version (i-body) have been developed into libraries containing a billion or more molecules that can be used to identify binders to a particular target to identify novel drug and diagnostic candidates.
Shark antibodies and i-bodies have high specificity and affinity for various therapeutic and diagnostic targets. They also have a number of advantages compared to traditional antibodies including a unique binding structure, specifically a very long CDR3 loop that can bind into hydrophobic grooves and receptor sites, providing the potential to bind drug targets that cannot be addressed by traditional antibodies. Shark antibodies and i-bodies are naturally small providing an ability to target various diseases more effectively and are manufactured in bacterial systems. Both the shark antibody and i-body are extremely stable at high temperatures and low pH for extended periods of time, giving rise to alternative delivery mechanisms beyond injection.
Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from Research & Development through Clinical Development as well as Sales, Marketing and Distribution.
Alchemia is an Australian biotechnology company engaged in the discovery and development of human therapeutic products.
Alchemia is a drug development company with late stage oncology product pipeline (Phase II and III), and an FDA approved drug (Fondaparinux).
Alchemia's pipeline of oncology products is built on the proprietary platform technology: HyACT
Alchemia is a drug development company with late stage oncology product pipeline (Phase II and III), and an FDA approved drug (Fondaparinux).
Alchemia's pipeline of oncology products is built on the proprietary platform technology: HyACT
Antisense Therapeutics? is an Australian publicly traded biopharmaceutical company. The Company?s R&D activities are focused on developing 2nd generation antisense drugs acquired from Isis Pharmaceuticals Inc, acknowledged world leaders in antisense drug development. The Company has 3 compounds in its development pipeline. ATL1103, which is in Phase II clinical trials for the orphan disease acromegaly. ATL1102, which has successfully completed a Phase II trial in Multiple Sclerosis patients, and ATL1101, in development as a potential cancer therapy
Aus Bio's mission is to discover, develop and commercialize new pharmaceuticals that benefit mankind. The company's current research and management philosophy is to focus on identifying chronic disease, conducting a cost effective and focused research and development programme, etc.
Avexa is engaged in the discovery and development of anti-infective pharmaceutical medicines for the treatment of serious human infectious diseases. The company's principal research programs focus on the discovery of innovative medicines for the treatment of the diseases caused by:
Human Immunodeficiency Virus (HIV);
Vancomycin- and methicillin-resistant bacteria.
Human Immunodeficiency Virus (HIV);
Vancomycin- and methicillin-resistant bacteria.
Benitec Biopharma Limited is a publicly listed (ASX:BLT) Australian-based biotechnology company developing novel treatments for chronic and life-threatening conditions based on its transformational gene silencing technology, DNA-directed RNA interference (ddRNAi, also known as vector expressed RNAi). Benitec holds the predominant patent position in the use of ddRNAi for human therapeutic and research applications.
BioDiem Ltd (BioDiem) is a Melbourne based company with an international focus on finding, adding value to and commercialising world class research for vaccines, infectious diseases and other therapeutic areas. BioDiem?s leading product is the Live Attenuated Influenza Virus (LAIV) technology, which has been used to develop a novel intranasal vaccine for seasonal and pandemic influenza.
Bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease.
Biotron Limited (Biotron, ASX:BIT) is a publicly listed Australian biotechnology company based in Sydney NSW. Biotron's primary focus is on development and commercialization of new mode of action, small molecule antiviral therapeutics targeting HIV-1 and Hepatitis C virus (HCV). Biotron has identified a new class of viral proteins as targets, and is developing novel small molecule drugs that target these proteins, specifically the Vpu protein of HIV and the p7 protein of HCV. Biotron's lead drug BIT225 is in development for treatment of both HIV and HCV, as well as the hard to treat HIV/HCV co-infected population. It offers the potential as a new class of oral direct-acting antiviral (DAA) drug for HCV that may be used with either current treatment strategies or with new classes of DAA?s currently in development.
Bioxyne Limited (ASX: BXN) is an Australian immunotherapeutics business, developing a lead product, HI-164OV, based upon proprietary technology utilising the application of mucosal immunology.
In addition to its immunotherapeutics, Bioxyne makes and sells consumer food supplements based on a proprietary probiotic based on a Lactobacillus fermentum strain.
In addition to its immunotherapeutics, Bioxyne makes and sells consumer food supplements based on a proprietary probiotic based on a Lactobacillus fermentum strain.
Cellmid is an Australian biotechnology company developing therapeutic and diagnostic products around a novel target, midkine. The Company's key programs include cancer diagnostic products and antibodies for the treatment of cancer and inflammatory conditions.